Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 12/20 | 0.67 |
| ▸ | SLC6A2 | P23975 | 11/20 | 0.67 |
| ▸ | HTR1A | P08908 | 10/20 | 0.67 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.67 |
| ▸ | HTR2C | P28335 | 2/20 | 0.54 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.48 |
| ▸ | HTR6 | P50406 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4701475 | 0.86 | SLC6A2 (0.64) | SLC6A4SLC6A2HTR1ASLC6A3HTR2C | |
| SCHEMBL4704178 | 0.86 | SLC6A2 (0.73) | SLC6A4SLC6A2HTR1ASLC6A3HTR2C | |
| SCHEMBL4700725 | 0.84 | HTR2C (0.59) | SLC6A4SLC6A2HTR1ASLC6A3HTR2C | |
| SCHEMBL4701461 | 0.81 | SLC6A2 (0.77) | SLC6A4SLC6A2HTR1ASLC6A3HTR2C | |
| SCHEMBL13770272 | 0.81 | SLC6A4 (1.00) | SLC6A4SLC6A2HTR1ASLC6A3HTR6 | |
| Hydrochloric Acid SCHEMBL4009907 | 0.80 | SLC6A4 (0.98) | SLC6A4SLC6A2HTR1ASLC6A3HTR6 | |
| SCHEMBL4702798 | 0.78 | SLC6A2 (0.71) | SLC6A4SLC6A2HTR1ASLC6A3HTR2C | |
| SCHEMBL4702823 | 0.78 | HTR1A (0.60) | SLC6A4SLC6A2HTR1ASLC6A3HTR2C | |
| SCHEMBL640909 | 0.77 | SLC6A4 (0.48) | SLC6A4SLC6A2HTR1ASLC6A3HTR2C | |
| SCHEMBL3385674 | 0.75 | SLC6A2 (0.52) | SLC6A4SLC6A2HTR1ASLC6A3HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1635828-B1 | 4-(2-PHENYLOXYPHENYL)-PIPERIDINE OR -1,2,3,6-TETRAHYDROPYRIDINE DERIVATIVES AS SEROTONIN REUPTAKE INHIBITORS | LUNDBECK & CO AS H (DK) | 2008-04-23 | — | — | EP | claimed |
| US-20060293360-A1 | 4-(2-Phenyloxyphenyl)-piperidine or-1,2,3,6-tetrahydropyridine derivatives as serotonin reuptake inhibitors | H. LUNDBECK A/S (DK) | 2006-12-28 | — | — | US | claimed |
| EP-1635828-B1 | 4-(2-PHENYLOXYPHENYL)-PIPERIDINE OR -1,2,3,6-TETRAHYDROPYRIDINE DERIVATIVES AS SEROTONIN REUPTAKE INHIBITORS | LUNDBECK & CO AS H (DK) | 2008-04-23 | — | — | EP | disclosed |
| EP-1583763-B1 | BENZOAZOLYLPIPERAZINE DERIVATIVES HAVING VR1-ANTAGONIST ACTIVITY | EURO CELTIQUE SA (LU) | 2008-03-26 | — | — | EP | disclosed |
| US-20060293360-A1 | 4-(2-Phenyloxyphenyl)-piperidine or-1,2,3,6-tetrahydropyridine derivatives as serotonin reuptake inhibitors | H. LUNDBECK A/S (DK) | 2006-12-28 | — | — | US | disclosed |
| EP-1635828-A1 | 4-(2-PHENYLOXYPHENYL)-PIPERIDINE OR -1,2,3,6-TETRAHYDROPYRIDINE DERIVATIVES AS SEROTONIN REUPTAKE INHIBITORS | H. Lundbeck A/S (DK) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004087155-A1 | 4-(2-PHENYLOXYPHENYL)-PIPERIDINE OR -1,2,3,6-TETRAHYDROPYRIDINE DERIVATIVES AS SEROTONIN REUPTAKE INHIBITORS | H. LUNDBECK A/S (DK) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293360-A1 | 4-(2-Phenyloxyphenyl)-piperidine or-1,2,3,6-tetrahydropyridine derivatives as serotonin reuptake inhibitors | HTR1D, TPH1, HTR2C | SLC6A4 11/4885SLC6A2 28/4885HTR1A 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.